JP2022512399A5 - - Google Patents

Info

Publication number
JP2022512399A5
JP2022512399A5 JP2021533537A JP2021533537A JP2022512399A5 JP 2022512399 A5 JP2022512399 A5 JP 2022512399A5 JP 2021533537 A JP2021533537 A JP 2021533537A JP 2021533537 A JP2021533537 A JP 2021533537A JP 2022512399 A5 JP2022512399 A5 JP 2022512399A5
Authority
JP
Japan
Prior art keywords
peaks
compound
scale
xrpd pattern
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021533537A
Other languages
English (en)
Japanese (ja)
Other versions
JP7509779B2 (ja
JP2022512399A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065972 external-priority patent/WO2020123800A1/en
Publication of JP2022512399A publication Critical patent/JP2022512399A/ja
Publication of JP2022512399A5 publication Critical patent/JP2022512399A5/ja
Priority to JP2023221085A priority Critical patent/JP7783870B2/ja
Application granted granted Critical
Publication of JP7509779B2 publication Critical patent/JP7509779B2/ja
Priority to JP2025208367A priority patent/JP2026031599A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021533537A 2018-12-13 2019-12-12 キナーゼ阻害剤の結晶性形態及び塩形態 Active JP7509779B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023221085A JP7783870B2 (ja) 2018-12-13 2023-12-27 キナーゼ阻害剤の結晶性形態及び塩形態
JP2025208367A JP2026031599A (ja) 2018-12-13 2025-11-28 キナーゼ阻害剤の結晶性形態及び塩形態

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862779430P 2018-12-13 2018-12-13
US62/779,430 2018-12-13
US201962856469P 2019-06-03 2019-06-03
US62/856,469 2019-06-03
PCT/US2019/065972 WO2020123800A1 (en) 2018-12-13 2019-12-12 Crystalline forms and salt forms of a kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023221085A Division JP7783870B2 (ja) 2018-12-13 2023-12-27 キナーゼ阻害剤の結晶性形態及び塩形態

Publications (3)

Publication Number Publication Date
JP2022512399A JP2022512399A (ja) 2022-02-03
JP2022512399A5 true JP2022512399A5 (cg-RX-API-DMAC7.html) 2022-12-19
JP7509779B2 JP7509779B2 (ja) 2024-07-02

Family

ID=69160358

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021533537A Active JP7509779B2 (ja) 2018-12-13 2019-12-12 キナーゼ阻害剤の結晶性形態及び塩形態
JP2023221085A Active JP7783870B2 (ja) 2018-12-13 2023-12-27 キナーゼ阻害剤の結晶性形態及び塩形態
JP2025208367A Pending JP2026031599A (ja) 2018-12-13 2025-11-28 キナーゼ阻害剤の結晶性形態及び塩形態

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023221085A Active JP7783870B2 (ja) 2018-12-13 2023-12-27 キナーゼ阻害剤の結晶性形態及び塩形態
JP2025208367A Pending JP2026031599A (ja) 2018-12-13 2025-11-28 キナーゼ阻害剤の結晶性形態及び塩形態

Country Status (33)

Country Link
US (2) US12017995B2 (cg-RX-API-DMAC7.html)
EP (2) EP4631505A3 (cg-RX-API-DMAC7.html)
JP (3) JP7509779B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250103803A (cg-RX-API-DMAC7.html)
CN (1) CN113329790A (cg-RX-API-DMAC7.html)
AU (2) AU2019395419B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011333A2 (cg-RX-API-DMAC7.html)
CA (1) CA3122840A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001537A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007613A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210375A (cg-RX-API-DMAC7.html)
DK (1) DK3894012T3 (cg-RX-API-DMAC7.html)
ES (1) ES3052838T3 (cg-RX-API-DMAC7.html)
FI (1) FI3894012T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20247596B (cg-RX-API-DMAC7.html)
HR (1) HRP20251122T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072868T2 (cg-RX-API-DMAC7.html)
IL (2) IL283860B2 (cg-RX-API-DMAC7.html)
LT (1) LT3894012T (cg-RX-API-DMAC7.html)
MA (1) MA54458B1 (cg-RX-API-DMAC7.html)
MD (1) MD3894012T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006951A (cg-RX-API-DMAC7.html)
PE (1) PE20211757A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551356A1 (cg-RX-API-DMAC7.html)
PL (1) PL3894012T4 (cg-RX-API-DMAC7.html)
PT (1) PT3894012T (cg-RX-API-DMAC7.html)
RS (1) RS67216B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105949RA (cg-RX-API-DMAC7.html)
SI (1) SI3894012T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500346T1 (cg-RX-API-DMAC7.html)
TW (2) TWI913821B (cg-RX-API-DMAC7.html)
WO (1) WO2020123800A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103844B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
KR102826380B1 (ko) * 2019-06-03 2025-06-26 엑셀리시스, 인코포레이티드 카이네이스 저해제의 결정질 염 형태
FI4143169T3 (fi) * 2020-04-30 2026-06-08 Exelixis Inc Kinaasi-inhibiittorin valmistusmenetelmät
PH12023550160A1 (en) 2020-07-31 2023-09-18 Exelixis Inc Combinations for the Treatment of Cancer
IL302485A (en) * 2020-11-05 2023-06-01 Exelixis Inc Kinase inhibitor pharmaceutical preparations
CN112650176B (zh) * 2020-12-22 2022-08-30 天能化工有限公司 一种盐酸解析开停车工序的dcs控制方法
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas
AU2022420610A1 (en) 2021-12-22 2024-06-27 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
CN116751161A (zh) * 2023-06-28 2023-09-15 中国人民解放军军事科学院军事医学研究院 喹啉类化合物及其制备方法、药物组合物及医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
JP4667537B2 (ja) 2008-04-10 2011-04-13 大鵬薬品工業株式会社 アシルチオウレア化合物又はその塩、及びその用途
AU2009303602B2 (en) 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
EA032757B1 (ru) 2014-02-14 2019-07-31 Экселиксис, Инк. Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
CN104817497B (zh) 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
MX2019012505A (es) 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
HRP20251184T1 (hr) 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
KR102826380B1 (ko) * 2019-06-03 2025-06-26 엑셀리시스, 인코포레이티드 카이네이스 저해제의 결정질 염 형태

Similar Documents

Publication Publication Date Title
KR102965826B1 (ko) 헤테로고리 화합물, 이의 제조 방법 및 이의 용도
JP7288904B2 (ja) ビアリールエーテル型キナゾリン誘導体
DK2970303T5 (en) SUBSTITUTED XANTHINES AND PROCEDURES FOR USING IT
JP6469567B2 (ja) Egfr発動性がんの細胞増殖阻害用化合物
CA2595834C (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
CA3029175C (en) Novel pyrazole derivatives as alk5 inhibitors and uses thereof
EP1406877A1 (en) Heterocyclic amines for the treatment of conditions associated with gsk-3
KR20180050405A (ko) B형 간염 코어 단백질 조정제
JP2015514060A5 (cg-RX-API-DMAC7.html)
KR102142797B1 (ko) 피리디닐아미노피리미딘 유도체의 메실레이트 염의 결정질 형태, 그의 제조 방법, 및 그의 용도
CN105263930A (zh) 作为lrrk2抑制剂的芳基吡咯并吡啶衍生的化合物
JP2022535072A5 (cg-RX-API-DMAC7.html)
KR20210102942A (ko) 치환된 아릴메틸우레아 및 헤테로아릴메틸우레아, 이의 유사체, 및 이의 사용 방법
JPWO2014021337A1 (ja) 精神神経疾患又は悪性腫瘍に関する化合物及び医薬組成物
JPWO2009041559A1 (ja) インダゾールアクリル酸アミド化合物
JP2016505584A (ja) ダウン症候群及びアルツハイマー病に関連する認知欠損の治療のための、dyrk1aタンパク質阻害剤としての3,5−ジアリールアザインドール類
WO2025153625A1 (en) Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
WO2025153624A1 (en) Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
JP2026511788A (ja) ピトリサント塩酸塩の多形形態
KR102114389B1 (ko) 신규 소듐채널 저해 화합물, 이의 제조방법, 및 이를 포함하는 소듐채널 관련 질환의 예방 또는 치료용 약학적 조성물
JP2022500441A5 (cg-RX-API-DMAC7.html)
KR102054640B1 (ko) 아데노신 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
KR20190128671A (ko) 중수소화 벤즈이미다졸 화합물 및 그의 의약 용도
CN109952296A (zh) 4-氰基-n-(2-(4,4-二甲基环己-1-烯-1-基)-6-(2,2,6,6-四甲基四氢-2h-吡喃-4-基)吡啶-3-基)-1h-咪唑-2-甲酰胺的结晶形式
CN108069937B (zh) 苯基哌啶衍生物及其使用方法和用途